Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth

Gastrointestinal stromal tumors (GISTs) comprise about 80% of mesenchymal neoplasms in the gastrointestinal tract. Although imatinib mesylate is the preferred treatment, the development of drug resistance highlights the need for novel therapeutic strategies. Recently, we have identified the micropht...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Guerrero, Elizabeth Proaño-Pérez, Eva Serrano-Candelas, Alfonso García-Valverde, Berenice Carrillo-Rodríguez, Jordi Rosell, César Serrano, Margarita Martin
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
MITF
cell survival
cell cycle
gastrointestinal stromal tumors
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000529
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329925000529

Similar Items